Zacks holds faith in Hospira; Indian drugmakers share ops efficiency tricks;

> Zacks has upgraded its rating on Hospira ($HSP) to neutral, from underperform; "negatives associated with the quality control issues have been priced into the stock," it said, and "[w]e believe the company's top and bottom-lines will rebound once the ongoing manufacturing issues get resolved." Item

> The LAZORR alliance of Indian drugmakers--Lupin, Aurobindo, Zydus, Orchid, Ranbaxy and Dr. Reddy's--has so far shared efficiency-improvement tactics for power and water savings. News

> Baxter ($BAX) is taking a dive into the biosimilars pool with Momenta Pharmaceuticals. Story

> Lundbeck ($LUN:DC) says it "is no longer able" to manufacture Mebaral CIV mephobarbital tablets and remaining inventory will expire in March. FDA list

> Botox sales are giving Allergan ($AGN) a boost--the pharma giant expects to create 200 jobs over four years at its plant in Ireland. Report

> Pacira Pharmaceuticals ($PCRX) projects commercial-level availability this coming April for Exparel, its non-opioid postsurgical analgesic approved by the FDA in October. Release

> Indian inspectors will conduct a 10-day tour next month of four Chinese bulk drug suppliers. Story

> Merck's ($MRK) life sciences division EMD Millipore will serve on the faculty of the Centre for Pharmaceutical Information and Engineering Research at Peking University, China. News

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.